These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 28492898)

  • 1. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
    Jänne PA; van den Heuvel MM; Barlesi F; Cobo M; Mazieres J; Crinò L; Orlov S; Blackhall F; Wolf J; Garrido P; Poltoratskiy A; Mariani G; Ghiorghiu D; Kilgour E; Smith P; Kohlmann A; Carlile DJ; Lawrence D; Bowen K; Vansteenkiste J
    JAMA; 2017 May; 317(18):1844-1853. PubMed ID: 28492898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
    Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
    Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
    Soria JC; Fülöp A; Maciel C; Fischer JR; Girotto G; Lago S; Smit E; Ostoros G; Eberhardt WEE; Lishkovska P; Lovick S; Mariani G; McKeown A; Kilgour E; Smith P; Bowen K; Kohlmann A; Carlile DJ; Jänne PA
    Ann Oncol; 2017 Dec; 28(12):3028-3036. PubMed ID: 29045535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
    Jänne PA; Mann H; Ghiorghiu D
    Clin Lung Cancer; 2016 Mar; 17(2):e1-4. PubMed ID: 26837474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
    Gupta A; Love S; Schuh A; Shanyinde M; Larkin JM; Plummer R; Nathan PD; Danson S; Ottensmeier CH; Lorigan P; Collins L; Wise A; Asher R; Lisle R; Middleton MR
    Ann Oncol; 2014 May; 25(5):968-74. PubMed ID: 24567366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS
    de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; Stollenwerk B; Waterhouse D; Paz-Ares L;
    Lancet; 2023 Mar; 401(10378):733-746. PubMed ID: 36764316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.
    Melosky B; Bradbury P; Tu D; Florescu M; Reiman A; Nicholas G; Basappa N; Rothenstein J; Goffin JR; Laurie SA; Wheatley-Price P; Leighl N; Goss G; Reaume MN; Butts C; Murray N; Card C; Ko J; Blais N; Gray S; Lui H; Brown-Walker P; Kaurah P; Prentice LM; Seymour L
    Lung Cancer; 2019 Jul; 133():48-55. PubMed ID: 31200828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
    Carter CA; Rajan A; Keen C; Szabo E; Khozin S; Thomas A; Brzezniak C; Guha U; Doyle LA; Steinberg SM; Xi L; Raffeld M; Tomita Y; Lee MJ; Lee S; Trepel JB; Reckamp KL; Koehler S; Gitlitz B; Salgia R; Gandara D; Vokes E; Giaccone G
    Ann Oncol; 2016 Apr; 27(4):693-9. PubMed ID: 26802155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
    Jänne PA; Smith I; McWalter G; Mann H; Dougherty B; Walker J; Orr MC; Hodgson DR; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios CH; Franke FA; Crinò L; Smith P
    Br J Cancer; 2015 Jul; 113(2):199-203. PubMed ID: 26125448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
    JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.
    Chung V; McDonough S; Philip PA; Cardin D; Wang-Gillam A; Hui L; Tejani MA; Seery TE; Dy IA; Al Baghdadi T; Hendifar AE; Doyle LA; Lowy AM; Guthrie KA; Blanke CD; Hochster HS
    JAMA Oncol; 2017 Apr; 3(4):516-522. PubMed ID: 27978579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
    Herbst RS; Sun Y; Eberhardt WE; Germonpré P; Saijo N; Zhou C; Wang J; Li L; Kabbinavar F; Ichinose Y; Qin S; Zhang L; Biesma B; Heymach JV; Langmuir P; Kennedy SJ; Tada H; Johnson BE
    Lancet Oncol; 2010 Jul; 11(7):619-26. PubMed ID: 20570559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
    Carvajal RD; Sosman JA; Quevedo JF; Milhem MM; Joshua AM; Kudchadkar RR; Linette GP; Gajewski TF; Lutzky J; Lawson DH; Lao CD; Flynn PJ; Albertini MR; Sato T; Lewis K; Doyle A; Ancell K; Panageas KS; Bluth M; Hedvat C; Erinjeri J; Ambrosini G; Marr B; Abramson DH; Dickson MA; Wolchok JD; Chapman PB; Schwartz GK
    JAMA; 2014 Jun; 311(23):2397-405. PubMed ID: 24938562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
    Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selumetinib in the treatment of non-small-cell lung cancer.
    Bernabé R; Patrao A; Carter L; Blackhall F; Dean E
    Future Oncol; 2016 Nov; 12(22):2545-2560. PubMed ID: 27467210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
    Heymach JV; Lockwood SJ; Herbst RS; Johnson BE; Ryan AJ
    Ann Oncol; 2014 Oct; 25(10):1941-1948. PubMed ID: 25057173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.